New data show TransCon hGH boosts TransCon CNP benefits in achondroplasia beyond growth.

Ascendis Pharma announced that Week 52 data from the Phase 2 COACH Trial reveal that combining TransCon hGH with TransCon CNP significantly improves arm span, spinal canal dimensions, and leg alignment in children with achondroplasia, beyond just linear growth. These improvements are meaningful to patients, potentially reducing complications like nerve compression and leg bowing. TransCon CNP is FDA-approved as YUVIWEL®, and TransCon hGH is approved as SKYTROFA®, with ongoing trials exploring their combined benefits. Longer-term data will be important to understand the full impact on skeletal health and quality of life.